You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version4.0
StatusDetected and Quantified
Creation Date2005-11-16 15:48:42 UTC
Update Date2019-04-01 19:19:55 UTC
HMDB IDHMDB0001429
Secondary Accession Numbers
  • HMDB0005947
  • HMDB01429
  • HMDB05947
Metabolite Identification
Common NamePhosphate
DescriptionPhosphate is a salt of phosphoric acid. In organic chemistry, a phosphate, or organophosphate, is an ester of phosphoric acid. Organic phosphates are important in biochemistry, biogeochemistry and ecology. Phosphate (Pi) is an essential component of life. In biological systems, phosphorus is found as a free phosphate ion in solution and is called inorganic phosphate, to distinguish it from phosphates bound in various phosphate esters. Inorganic phosphate is generally denoted Pi and at physiological (neutral) pH primarily consists of a mixture of HPO2-4 and H2PO-4 ions. phosphates are most commonly found in the form of adenosine phosphates, (AMP, ADP and ATP) and in DNA and RNA and can be released by the hydrolysis of ATP or ADP. Similar reactions exist for the other nucleoside diphosphates and triphosphates. Phosphoanhydride bonds in ADP and ATP, or other nucleoside diphosphates and triphosphates, contain high amounts of energy which give them their vital role in all living organisms. Phosphate must be actively transported into cells against its electrochemical gradient. In vertebrates, two unrelated families of Na+-dependent Pi transporters carry out this task. Remarkably, the two families transport different Pi species: whereas type II Na+/Pi cotransporters (SCL34) prefer divalent HPO4(2), type III Na+/Pi cotransporters (SLC20) transport monovalent H2PO4. The SCL34 family comprises both electrogenic and electroneutral members that are expressed in various epithelia and other polarized cells. Through regulated activity in apical membranes of the gut and kidney, they maintain body Pi homeostasis, and in salivary and mammary glands, liver, and testes they play a role in modulating the Pi content of luminal fluids. Phosphate levels in the blood play an important role in hormone signaling and in bone homeostasis. In classical endocrine regulation, low serum phosphate induces the renal production of the seco-steroid hormone 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). This active metabolite of vitamin D acts to restore circulating mineral (i.e. phosphate and calcium) levels by increasing absorption in the intestine, reabsorption in the kidney, and mobilization of calcium and phosphate from bone. Thus, chronic renal failure is associated with hyperparathyroidism, which in turn contributes to osteomalacia (softening of the bones). Another complication of chronic renal failure is hyperphosphatemia (low levels of phosphate in the blood). Hyperphosphatemia (excess levels of phosphate in the blood) is a prevalent condition in kidney dialysis patients and is associated with increased risk of mortality. Hypophosphatemia (hungry bone syndrome) has been associated to postoperative electrolyte aberrations and after parathyroidectomy (PMID: 17581921 , 11169009 , 11039261 , 9159312 , 17625581 ). Fibroblast growth factor 23 (FGF-23) has recently been recognized as a key mediator of phosphate homeostasis, its most notable effect being promotion of phosphate excretion. FGF-23 was discovered to be involved in diseases such as autosomal dominant hypophosphatemic rickets, X-linked hypophosphatemia, and tumor-induced osteomalacia in which phosphate wasting was coupled to inappropriately low levels of 1,25(OH)2D3. FGF-23 is regulated by dietary phosphate in humans. In particular it was found that phosphate restriction decreased FGF-23, and phosphate loading increased FGF-23.
Structure
Data?1547234159
Synonyms
ValueSource
[PO(OH)3]ChEBI
Acide phosphoriqueChEBI
Acidum phosphoricumChEBI
H3PO4ChEBI
Orthophosphoric acidChEBI
PhosphateChEBI
PhosphorsaeureloesungenChEBI
PhosphorsaeureChEBI
Phosphoric acidKegg
OrthophosphateGenerator
Hydrogen phosphoric acidGenerator
Diphosphate tetrasodiumHMDB
MarphosHMDB
NFBHMDB
Ortho- phosphoric acidHMDB
Phosphoric acid (acd/name 4.0)HMDB
Sodium pyrophosphateHMDB
Sodium pyrophosphate decahydrateHMDB
Sodium pyrophosphate decahydrate biochemicaHMDB
SonacHMDB
Tetra-sodium pyrophosphateHMDB
Tetrasodium pyrophosphate 10-hydrateHMDB
Tetrasodium pyrophosphate decahydrateHMDB
White phosphoric acidHMDB
K-EtchantHMDB
Uni-etchHMDB
Concise etchantHMDB
CondactMeSH
Chemical FormulaH3O4P
Average Molecular Weight97.9952
Monoisotopic Molecular Weight97.976895096
IUPAC Namephosphoric acid
Traditional Namephosphoric acid
CAS Registry Number14265-44-2
SMILES
OP(O)(O)=O
InChI Identifier
InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)
InChI KeyNBIIXXVUZAFLBC-UHFFFAOYSA-N
Chemical Taxonomy
Description belongs to the class of inorganic compounds known as non-metal phosphates. These are inorganic non-metallic compounds containing a phosphate as its largest oxoanion.
KingdomInorganic compounds
Super ClassHomogeneous non-metal compounds
ClassNon-metal oxoanionic compounds
Sub ClassNon-metal phosphates
Direct ParentNon-metal phosphates
Alternative Parents
Substituents
  • Non-metal phosphate
  • Inorganic oxide
Molecular FrameworkNot Available
External Descriptors
Ontology
Physiological effect

Health effect:

Disposition

Route of exposure:

Source:

Biological location:

Process

Naturally occurring process:

Role

Biological role:

Physical Properties
StateSolid
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility1000 mg/mLMERCK INDEX (1996)
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP-1ChemAxon
pKa (Strongest Acidic)1.8ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area77.76 ŲChemAxon
Rotatable Bond Count0ChemAxon
Refractivity14.65 m³·mol⁻¹ChemAxon
Polarizability5.81 ųChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Spectrum TypeDescriptionSplash KeyView
GC-MSGC-MS Spectrum - GC-MS (3 TMS)splash10-0002-0794000000-6c866e626b9356994d46JSpectraViewer | MoNA
GC-MSGC-MS Spectrum - EI-B (Non-derivatized)splash10-0002-0394000000-3a469377821d88bd699fJSpectraViewer | MoNA
GC-MSGC-MS Spectrum - GC-MS (Non-derivatized)splash10-0002-0794000000-6c866e626b9356994d46JSpectraViewer | MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Non-derivatized)splash10-000t-0972000000-2ddd7182426dbace5342JSpectraViewer | MoNA
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positivesplash10-0002-9000000000-1805c2208b5ff15a75b1JSpectraViewer | MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)splash10-000t-9000000000-0e85f764ac98e8949759JSpectraViewer | MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)splash10-001i-9000000000-869a362083996a0cec77JSpectraViewer | MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)splash10-03di-9000000000-801101cccfd6c25271d4JSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0002-9000000000-12a5e23d24cd494e99c1JSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0002-9000000000-91e06ca38117aabdb14cJSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-000t-9000000000-19b1c041aa5e2adcc3e6JSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0002-9000000000-e56eecd6724dfbf74160JSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-004i-9000000000-0a46ba32971030356ac5JSpectraViewer | MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-004i-9000000000-3a53d27e23b39429d092JSpectraViewer | MoNA
Biological Properties
Cellular Locations
  • Cytoplasm
  • Extracellular
  • Mitochondria
  • Nucleus
  • Lysosome
  • Endoplasmic reticulum
  • Golgi apparatus
  • Peroxisome
Biospecimen Locations
  • Blood
  • Feces
  • Saliva
  • Sweat
  • Urine
Tissue Locations
  • Kidney
  • Liver
  • Prostate
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected and Quantified379.1 +/- 31.6 uMAdult (>18 years old)MaleNormal details
BloodDetected and Quantified1400-2200 uMNot SpecifiedNot SpecifiedNormal details
BloodDetected and Quantified2800 uMInfant (0-1 year old)FemalePyroglutamic aciduria details
BloodDetected and Quantified589.65-1105.60 uMNewborn (0 - <14 days old)Both
Normal
    • CALIPER Paediatri...
details
BloodDetected and Quantified505.42-884.45 uMInfant (15 days - <1 year old)Both
Normal
    • CALIPER Paediatri...
details
BloodDetected and Quantified452.77-716.01 uMChildren (1 - <5 years old)Both
Normal
    • CALIPER Paediatri...
details
BloodDetected and Quantified431.71-621.24 uMChildren (5 - <13 years old)Both
Normal
    • CALIPER Paediatri...
details
BloodDetected and Quantified336.94-579.12 uMAdolescent (13 - <16 years old)Female
Normal
    • CALIPER Paediatri...
details
BloodDetected and Quantified305.36-526.47 uMAdolescent (16 - <19 years old)Both
Normal
    • CALIPER Paediatri...
details
BloodDetected and Quantified368.53-652.83 uMAdolescent (13 - <16 years old)Male
Normal
    • CALIPER Paediatri...
details
BloodDetected and Quantified1100 +/- 190 uMAdult (>18 years old)BothNormal details
BloodDetected and Quantified1200-1960 uMInfant (0-1 year old)Not SpecifiedNormal details
BloodDetected and Quantified400.120-684.417 uMChildren (1-13 years old)Not SpecifiedNormal details
BloodDetected and Quantified1200-2000 uMInfant (0-1 year old)Not SpecifiedNormal details
BloodDetected and Quantified1000-2200 uMChildren (1-13 years old)Not SpecifiedNormal details
FecesDetected but not Quantified Infant (0-1 year old)Not Specified
Normal
details
FecesDetected but not Quantified Infant (0-1 year old)Not Specified
Normal
details
FecesDetected but not Quantified Infant (0-1 year old)Not AvailableNormal details
FecesDetected but not Quantified Adult (>18 years old)Both
Normal
details
FecesDetected but not Quantified Adult (>18 years old)Both
Normal
details
FecesDetected but not Quantified Adult (>18 years old)Both
Normal
details
SalivaDetected and Quantified27850 +/- 36040 uMAdult (>18 years old)Both
Normal
details
SalivaDetected and Quantified28550 +/- 33790 uMAdult (>18 years old)Both
Normal
details
SalivaDetected and Quantified21450 +/- 21020 uMAdult (>18 years old)Both
Normal
details
SalivaDetected and Quantified17620 +/- 13800 uMAdult (>18 years old)Both
Normal
details
SalivaDetected and Quantified21630 +/- 15830 uMAdult (>18 years old)Both
Normal
details
SalivaDetected and Quantified24100 +/- 16390 uMAdult (>18 years old)Both
Normal
details
SalivaDetected and Quantified22690 +/- 19270 uMAdult (>18 years old)Both
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected but not Quantified Adult (>18 years old)Male
Normal
details
SalivaDetected and Quantified2787.81 +/- 1528.51 uMAdult (>18 years old)BothNormal
    • Zerihun T. Dame, ...
details
SweatDetected but not Quantified Adult BothNormal details
UrineDetected and Quantified1364.27 +/- 915.27 umol/mmol creatinineInfant (0-1 year old)BothNormal details
UrineDetected but not Quantified Adult (>18 years old)BothNormal details
Abnormal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected and Quantified450 +/- 30 uMAdult (>18 years old)Not Specified
Hypophosphatemia
details
BloodDetected and Quantified290 +/- 50 uMAdult (>18 years old)Not Specified
Hypophosphatemia
details
BloodDetected and Quantified653.0 +/- 126.0 uMAdult (>18 years old)BothHemodialysis details
BloodDetected and Quantified2700-4700 uMInfant (0-1 year old)BothHypoparathyroidism-retardation-dysmorphism syndrome details
BloodDetected and Quantified1300 +/- 170 uMAdult (>18 years old)Both
Hypophosphatasia, infantile
details
BloodDetected and Quantified126.354 uMAdult (>18 years old)FemaleFanconi syndrome details
BloodDetected and Quantified315.885 uMChildren (1-13 years old)FemaleHyperphosphatasia details
BloodDetected and Quantified270 (0-540) uMAdult (>18 years old)Not Specified
Hypophosphatemia
details
BloodDetected and Quantified610 +/- 130 uMAdult (>18 years old)Not Specified
Hypophosphatemia
details
BloodDetected and Quantified1700-2000 uMInfant (0-1 year old)Not SpecifiedOculocerebrorenal Syndrome of Lowe details
BloodDetected and Quantified900-2000 uMChildren (1-13 years old)Not SpecifiedOculocerebrorenal Syndrome of Lowe details
BloodDetected and Quantified800-1400 uMAdolescent (13-18 years old)Not SpecifiedOculocerebrorenal Syndrome of Lowe details
BloodDetected and Quantified1000-1300 uMAdult (>18 years old)Not SpecifiedOculocerebrorenal Syndrome of Lowe details
BloodDetected and Quantified231.649 uMAdult (>18 years old)Male
Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness
details
FecesDetected but not Quantified Adult (>18 years old)Both
Colorectal cancer
details
FecesDetected but not Quantified Adult (>18 years old)Both
Colorectal cancer
details
FecesDetected but not Quantified Adult (>18 years old)BothColorectal Cancer details
UrineDetected but not Quantified Adult (>18 years old)BothBladder cancer details
Associated Disorders and Diseases
Disease References
Hemodialysis
  1. Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N, Matsumoto K: Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol. 2007 Dec;11(4):304-8. Epub 2007 Dec 21. [PubMed:18085392 ]
Hypophosphatemia
  1. Amanzadeh J, Reilly RF Jr: Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol. 2006 Mar;2(3):136-48. [PubMed:16932412 ]
Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness
  1. Heilberg IP, Totoli C, Calado JT: Adult presentation of Bartter syndrome type IV with erythrocytosis. Einstein (Sao Paulo). 2015 Oct-Dec;13(4):604-6. doi: 10.1590/S1679-45082015RC3013. Epub 2015 Oct 30. [PubMed:26537508 ]
Fanconi syndrome
  1. Cheng HM, Jap TS, Ho LT: Fanconi syndrome: report of a case. J Formos Med Assoc. 1990 Dec;89(12):1115-7. [PubMed:1982686 ]
Hyperphosphatasia
  1. Saki F, Karamizadeh Z, Nasirabadi S, Mumm S, McAlister WH, Whyte MP: Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation. J Bone Miner Res. 2013 Jun;28(6):1501-8. doi: 10.1002/jbmr.1868. [PubMed:23322328 ]
Hypoparathyroidism-retardation-dysmorphism syndrome
  1. Sanjad SA, Sakati NA, Abu-Osba YK, Kaddoura R, Milner RD: A new syndrome of congenital hypoparathyroidism, severe growth failure, and dysmorphic features. Arch Dis Child. 1991 Feb;66(2):193-6. [PubMed:2001103 ]
Hypophosphatasia
  1. Chodirker BN, Evans JA, Seargeant LE, Cheang MS, Greenberg CR: Hyperphosphatemia in infantile hypophosphatasia: implications for carrier diagnosis and screening. Am J Hum Genet. 1990 Feb;46(2):280-5. [PubMed:2301398 ]
Oculocerebrorenal syndrome
  1. Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904. [PubMed:2017228 ]
Colorectal cancer
  1. Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
  2. Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
  3. Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
Associated OMIM IDs
  • 602522 (Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness)
  • 239000 (Hyperphosphatasia)
  • 241410 (Hypoparathyroidism-retardation-dysmorphism syndrome)
  • 241500 (Hypophosphatasia)
  • 309000 (Oculocerebrorenal syndrome)
  • 114500 (Colorectal cancer)
DrugBank IDDB09394
Phenol Explorer Compound IDNot Available
FoodDB IDFDB013380
KNApSAcK IDC00007408
Chemspider ID979
KEGG Compound IDC00009
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkPhosphoric_Acid
METLIN IDNot Available
PubChem Compound1004
PDB IDNot Available
ChEBI ID26078
References
Synthesis ReferenceCremer, Josef; Hartmann, Fridolin; Rodis, Franz; Hinz, Arnulf. Preparation of alkali or alkaline earth phosphates with simultaneous recovery of volatile mineral acids. Ger. (1966), 2 pp. CODEN: GWXXAW DE 1227435 19661027 CAN 66:12584 AN 1967:12584
Material Safety Data Sheet (MSDS)Download (PDF)
General References
  1. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
  2. Hem SL, Hogenesch H: Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines. 2007 Oct;6(5):685-98. [PubMed:17931150 ]
  3. Srivastava T, Alon US: Pathophysiology of hypercalciuria in children. Pediatr Nephrol. 2007 Oct;22(10):1659-73. Epub 2007 Apr 27. [PubMed:17464515 ]
  4. Pietak AM, Reid JW, Stott MJ, Sayer M: Silicon substitution in the calcium phosphate bioceramics. Biomaterials. 2007 Oct;28(28):4023-32. Epub 2007 May 17. [PubMed:17544500 ]
  5. Keul P, Sattler K, Levkau B: HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev. 2007 Dec;12(3-4):301-6. [PubMed:17554629 ]
  6. Isales CM, McDonald JM: Future developments in therapy. Ann N Y Acad Sci. 2007 Nov;1117:258-63. Epub 2007 Jun 21. [PubMed:17584984 ]
  7. Pumo V, Sciacca D, Malaguarnera M: Tumor lysis syndrome in elderly. Crit Rev Oncol Hematol. 2007 Oct;64(1):31-42. Epub 2007 Jul 19. [PubMed:17658268 ]
  8. Breitkreutz D, Braiman-Wiksman L, Daum N, Denning MF, Tennenbaum T: Protein kinase C family: on the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol. 2007 Nov;133(11):793-808. Epub 2007 Jul 28. [PubMed:17661083 ]
  9. Tiwari S, Riazi S, Ecelbarger CA: Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol. 2007 Oct;293(4):F974-84. Epub 2007 Aug 8. [PubMed:17686957 ]
  10. Argraves KM, Argraves WS: HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res. 2007 Nov;48(11):2325-33. Epub 2007 Aug 13. [PubMed:17698855 ]
  11. Brown BA, Kantesaria PP, McDevitt LM: Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother. 2007 Oct;41(10):1660-8. Epub 2007 Sep 4. [PubMed:17785617 ]
  12. Toussaint ND, Kerr PG: Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology (Carlton). 2007 Oct;12(5):500-9. [PubMed:17803475 ]
  13. Munteanu A, Zingg JM: Cellular, molecular and clinical aspects of vitamin E on atherosclerosis prevention. Mol Aspects Med. 2007 Oct-Dec;28(5-6):538-90. Epub 2007 Aug 3. [PubMed:17825403 ]
  14. Nauseef WM: How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev. 2007 Oct;219:88-102. [PubMed:17850484 ]
  15. Allen LA, McCaffrey RL: To activate or not to activate: distinct strategies used by Helicobacter pylori and Francisella tularensis to modulate the NADPH oxidase and survive in human neutrophils. Immunol Rev. 2007 Oct;219:103-17. [PubMed:17850485 ]
  16. Giavazzi R, Bani MR, Taraboletti G: Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer Metastasis Rev. 2007 Dec;26(3-4):481-8. [PubMed:17896168 ]
  17. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B: Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007 Oct;22(10):2856-66. [PubMed:17906326 ]
  18. Miyamoto K, Tatsumi S, Ito M, Segawa H: [New aspect of renal phosphate reabsorption and phosphate metabolism]. Clin Calcium. 2007 Oct;17(10):1485-92. [PubMed:17906398 ]
  19. Michigami T: [Vitamin D metabolism and action]. Clin Calcium. 2007 Oct;17(10):1493-8. [PubMed:17906399 ]
  20. Hoshi K: [Mechanisms of bone calcification]. Clin Calcium. 2007 Oct;17(10):1499-507. [PubMed:17906400 ]
  21. Takeuchi Y: [Pathophysiology in rickets/osteomalacia]. Clin Calcium. 2007 Oct;17(10):1508-13. [PubMed:17906401 ]
  22. Ito N, Fukumoto S: [FGF23-related hypophosphatemic rickets/osteomalacia]. Clin Calcium. 2007 Oct;17(10):1514-20. [PubMed:17906402 ]
  23. Sekine T: [Rickets/osteomalacia due to tubular dysfunction]. Clin Calcium. 2007 Oct;17(10):1529-33. [PubMed:17906404 ]
  24. Sato K: [Drug-induced osteomalacia]. Clin Calcium. 2007 Oct;17(10):1536-42. [PubMed:17906405 ]
  25. Hasegawa Y, Miyamoto J: [Hypophosphatemic rickets/osteomalacia. - Mainly on patients with PHEX mutations -]. Clin Calcium. 2007 Oct;17(10):1592-9. [PubMed:17906414 ]
  26. Bragadeesh TK, Mathur G, Clark AL, Cleland JG: Novel cardiac myosin activators for acute heart failure. Expert Opin Investig Drugs. 2007 Oct;16(10):1541-8. [PubMed:17922619 ]
  27. Worthington HV, Clarkson JE, Eden OB: Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000978. [PubMed:17943748 ]
  28. Nixon GF, Mathieson FA, Hunter I: The potential roles of sphingolipids in vascular smooth-muscle function. Biochem Soc Trans. 2007 Nov;35(Pt 5):908-9. [PubMed:17956243 ]
  29. Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ: Glucokinase activators: molecular tools for studying the physiology of insulin-secreting cells. Biochem Soc Trans. 2007 Nov;35(Pt 5):1208-10. [PubMed:17956314 ]
  30. Ku NO, Strnad P, Zhong BH, Tao GZ, Omary MB: Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. Hepatology. 2007 Nov;46(5):1639-49. [PubMed:17969036 ]
  31. Beutler E, Duparc S: Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007 Oct;77(4):779-89. [PubMed:17978087 ]
  32. Van Brocklyn JR: Sphingolipid signaling pathways as potential therapeutic targets in gliomas. Mini Rev Med Chem. 2007 Oct;7(10):984-90. [PubMed:17979800 ]
  33. Raben DM, Tu-Sekine B: Nuclear diacylglycerol kinases: regulation and roles. Front Biosci. 2008 Jan 1;13:590-7. [PubMed:17981572 ]
  34. Dubin A, Estenssoro E: Mechanisms of tissue hypercarbia in sepsis. Front Biosci. 2008 Jan 1;13:1340-51. [PubMed:17981634 ]
  35. Deng ZL, Sharff KA, Tang N, Song WX, Luo J, Luo X, Chen J, Bennett E, Reid R, Manning D, Xue A, Montag AG, Luu HH, Haydon RC, He TC: Regulation of osteogenic differentiation during skeletal development. Front Biosci. 2008 Jan 1;13:2001-21. [PubMed:17981687 ]
  36. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, Bielawski J, Dong JY, El-Zawahry AM, Guo GW, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Keane TE, Tavassoli M, Norris JS: Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 1;13:2293-8. [PubMed:17981711 ]
  37. Su N, Du X, Chen L: FGF signaling: its role in bone development and human skeleton diseases. Front Biosci. 2008 Jan 1;13:2842-65. [PubMed:17981758 ]
  38. Trimble JL, Kockler DR: Statin treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Ann Pharmacother. 2007 Dec;41(12):2019-23. Epub 2007 Nov 6. [PubMed:17986515 ]
  39. Zeitels SM, Burns JA: Office-based laryngeal laser surgery with the 532-nm pulsed-potassium-titanyl-phosphate laser. Curr Opin Otolaryngol Head Neck Surg. 2007 Dec;15(6):394-400. [PubMed:17986877 ]
  40. Pebay A, Bonder CS, Pitson SM: Stem cell regulation by lysophospholipids. Prostaglandins Other Lipid Mediat. 2007 Nov;84(3-4):83-97. Epub 2007 Sep 5. [PubMed:17991611 ]
  41. Komarova YA, Mehta D, Malik AB: Dual regulation of endothelial junctional permeability. Sci STKE. 2007 Nov 13;2007(412):re8. [PubMed:18000237 ]
  42. Burger EL, Patel V: Calcium phosphates as bone graft extenders. Orthopedics. 2007 Nov;30(11):939-42. [PubMed:18019987 ]
  43. Qin C, D'Souza R, Feng JQ: Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J Dent Res. 2007 Dec;86(12):1134-41. [PubMed:18037646 ]
  44. Andress DL: Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Clin J Am Soc Nephrol. 2008 Jan;3(1):179-83. Epub 2007 Dec 5. [PubMed:18057310 ]
  45. Fukumoto S: [Parathyroid and bone. Calcimimetics and bone metabolism]. Clin Calcium. 2007 Dec;17(12):1865-9. [PubMed:18057662 ]
  46. Fei X, Qin Z, Liang Z: Contribution of CDP/Cux, a transcription factor, to cell cycle progression. Acta Biochim Biophys Sin (Shanghai). 2007 Dec;39(12):923-30. [PubMed:18064384 ]
  47. Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R: Atherosclerosis and oxidative stress. Histol Histopathol. 2008 Mar;23(3):381-90. doi: 10.14670/HH-23.381. [PubMed:18072094 ]
  48. Orcel P, Chapurlat R: [Fibrous dysplasia of bone]. Rev Prat. 2007 Oct 31;57(16):1749-55. [PubMed:18092715 ]
  49. Damron TA: Use of 3D beta-tricalcium phosphate (Vitoss) scaffolds in repairing bone defects. Nanomedicine (Lond). 2007 Dec;2(6):763-75. [PubMed:18095844 ]
  50. Hertz A, Bruce IJ: Inorganic materials for bone repair or replacement applications. Nanomedicine (Lond). 2007 Dec;2(6):899-918. [PubMed:18095853 ]
  51. Cappellini MD, Fiorelli G: Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008 Jan 5;371(9606):64-74. doi: 10.1016/S0140-6736(08)60073-2. [PubMed:18177777 ]
  52. Virkki LV, Biber J, Murer H, Forster IC: Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol. 2007 Sep;293(3):F643-54. Epub 2007 Jun 20. [PubMed:17581921 ]
  53. Pohlmeier R, Vienken J: Phosphate removal and hemodialysis conditions. Kidney Int Suppl. 2001 Feb;78:S190-4. [PubMed:11169009 ]
  54. Gallar P, Ortega O, Gutierrez M, Munoz M, Hilara L, Oliet A, Rodriguez I, Gimenez E, Vigil A: [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options]. Nefrologia. 2000 Jul-Aug;20(4):355-61. [PubMed:11039261 ]
  55. Cruz DN, Perazella MA: Biochemical aberrations in a dialysis patient following parathyroidectomy. Am J Kidney Dis. 1997 May;29(5):759-62. [PubMed:9159312 ]
  56. Nemere I: The ins and outs of phosphate homeostasis. Kidney Int. 2007 Jul;72(2):140-2. [PubMed:17625581 ]

Only showing the first 10 proteins. There are 330 proteins in total.

Enzymes

General function:
Involved in nucleotide binding
Specific function:
Dephosphorylates the 5' and 2'(3')-phosphates of deoxyribonucleotides. Helps to regulate adenosine levels (By similarity).
Gene Name:
NT5C1B
Uniprot ID:
Q96P26
Molecular weight:
68803.055
General function:
Involved in nucleotide binding
Specific function:
Dephosphorylates the 5' and 2'(3')-phosphates of deoxyribonucleotides and has a broad substrate specificity. Helps to regulate adenosine levels in heart during ischemia and hypoxia.
Gene Name:
NT5C1A
Uniprot ID:
Q9BXI3
Molecular weight:
41020.145
General function:
Involved in metal ion binding
Specific function:
Dephosphorylates the 5' and 2'(3')-phosphates of deoxyribonucleotides, with a preference for dUMP and dTMP, intermediate activity towards dGMP, and low activity towards dCMP and dAMP.
Gene Name:
NT5C
Uniprot ID:
Q8TCD5
Molecular weight:
Not Available
General function:
Involved in phosphatase activity
Specific function:
Dephosphorylates specifically the 5' and 2'(3')-phosphates of uracil and thymine deoxyribonucleotides, and so protects mitochondrial DNA replication from excess dTTP. Has only marginal activity towards dIMP and dGMP.
Gene Name:
NT5M
Uniprot ID:
Q9NPB1
Molecular weight:
Not Available
General function:
Involved in ATP citrate synthase activity
Specific function:
ATP citrate-lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Has a central role in de novo lipid synthesis. In nervous tissue it may be involved in the biosynthesis of acetylcholine.
Gene Name:
ACLY
Uniprot ID:
P53396
Molecular weight:
120838.27
General function:
Involved in acetyl-CoA carboxylase activity
Specific function:
ACC-beta may be involved in the provision of malonyl-CoA or in the regulation of fatty acid oxidation, rather than fatty acid biosynthesis. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase.
Gene Name:
ACACB
Uniprot ID:
O00763
Molecular weight:
276538.575
General function:
Involved in catalytic activity
Specific function:
Pyruvate carboxylase catalyzes a 2-step reaction, involving the ATP-dependent carboxylation of the covalently attached biotin in the first step and the transfer of the carboxyl group to pyruvate in the second. Catalyzes in a tissue specific manner, the initial reactions of glucose (liver, kidney) and lipid (adipose tissue, liver, brain) synthesis from pyruvate.
Gene Name:
PC
Uniprot ID:
P11498
Molecular weight:
129632.565
General function:
Involved in acetyl-CoA carboxylase activity
Specific function:
Catalyzes the rate-limiting reaction in the biogenesis of long-chain fatty acids. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase.
Gene Name:
ACACA
Uniprot ID:
Q13085
Molecular weight:
269997.01
General function:
Involved in hydrolase activity
Specific function:
In the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well.
Gene Name:
ENTPD1
Uniprot ID:
P49961
Molecular weight:
58706.0
General function:
Involved in calcium ion binding
Specific function:
Calcium-dependent nucleotidase with a preference for UDP. The order of activity with different substrates is UDP > GDP > UTP > GTP. Has very low activity towards ADP and even lower activity towards ATP. Does not hydrolyze AMP and GMP. Involved in proteoglycan synthesis.
Gene Name:
CANT1
Uniprot ID:
Q8WVQ1
Molecular weight:
44839.24

Transporters

General function:
Involved in ATP binding
Specific function:
Involved in the export of copper out of the cells, such as the efflux of hepatic copper into the bile.
Gene Name:
ATP7B
Uniprot ID:
P35670
Molecular weight:
157261.34
General function:
Involved in ATP binding
Specific function:
May supply copper to copper-requiring proteins within the secretory pathway, when localized in the trans-Golgi network. Under conditions of elevated extracellular copper, it relocalized to the plasma membrane where it functions in the efflux of copper from cells.
Gene Name:
ATP7A
Uniprot ID:
Q04656
Molecular weight:
163372.275

Only showing the first 10 proteins. There are 330 proteins in total.